ClinicalTrials.gg
CompletedNCT07456800Updated Mar 6, 2026

PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects

A Phase 1 interventional study of Deupirfenidone and Pirfenidone (PFD) in Pharmacokinetic Analysis, sponsored by PureTech. Completed at 3 sites in United States. Open to participants aged 60 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by PureTech · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jan 2022, 4 years 10 months ago, and no results have been posted to the registry.
  • Registered 4 years 7 months after the study started (first participant enrolled Jul 2021, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Study summary

A three-part, randomized, double-blind study in healthy older adults to identify a dose of deupirfenidone for further clinical study.

Read the detailed description

A Phase 1 study to evaluate safety, tolerability, and PK in older healthy subjects of multiple twice daily (BID) or 3 times daily (TID) doses of deupirfenidone administered over 3 days compared to that of pirfenidone or placebo administered TID. The study also investigated the PK profile of deupirfenidone at steady state compared to that of pirfenidone at steady state and the effect of food on the PK profile of deupirfenidone and pirfenidone. The study was conducted in 3 parts. Part 1 was a randomized, double-blinded, two-period crossover study conducted in healthy older adults to evaluate the tolerability differentiation of BID dosing of deupirfenidone to pirfenidone. Part 2 was a randomized, double-blinded, two-period crossover study conducted in healthy older adults to evaluate the tolerability differentiation of TID dosing of deupirfenidone to pirfenidone. Part 3 was a randomized, double-blinded, parallel arm, placebo-controlled study conducted in healthy older adults to evaluate the safety and tolerability of two doses of deupirfenidone.

02

Conditions studied

  • Pharmacokinetic Analysis

Keywords

  • deupirfenidone
  • pirfenidone
  • PK
  • pharmacokinetics
  • elderly
03

In context

Lead sponsor

PureTech is the lead sponsor of 9 studies on the registry; 1 is open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • Male or female between 60 and 80 years old (inclusive) at the time of Screening.
  • In good general health at Screening, free from laboratory values, or clinically significant unstable medical, surgical, or psychiatric illness, as determined by the Investigator. Subjects with mild, chronic, stable disease and on stable medication could be included if deemed medically prudent by the Investigator.
  • Has a (BMI) between ≥18.0 and ≤50.0 kg/m2 at Screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    Part 1 Active

    deupirfenidone 850 mg BID

    Drug: Deupirfenidone

  • Active comparator
    Part 1 Active Comparator

    pirfenidone 801 mg TID

    Drug: Pirfenidone (PFD)

  • Experimental
    Part 2 Active

    deupirfenidone 550 mg TID

    Drug: Deupirfenidone

  • Active comparator
    Part 2 Active Comparator

    pirfenidone 801 mg TID

    Drug: Pirfenidone (PFD)

  • Experimental
    Part 3 Active

    deupirfenidone 550/824 mg TID

    Drug: Deupirfenidone

  • Placebo comparator
    Part 3 Placebo

    placebo TID

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Cmax of BID deupirfenidone versus TID pirfenidone

    To compare the Cmax of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered in a two-period crossover design.

    Time frame: 14 days

  2. Part 2: Cmax of TID deupirfenidone versus TID pirfenidone

    To compare the Cmax of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered in a two-period crossover design.

    Time frame: 14 days

  3. Part 3: Cmax of TID deupirfenidone versus placebo

    To evaluate the Cmax of two doses of deupirfenidone.

    Time frame: 6 days

  4. Part 1: AUC of BID deupirfenidone versus TID pirfenidone

    To compare the AUC of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered in a two-period crossover design.

    Time frame: 14 Days

  5. Part 1: Tmax of BID deupirfenidone versus TID pirfenidone

    To compare the Tmax of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered in a two-period crossover design.

    Time frame: 14 Days

  6. Part 2: AUC of TID deupirfenidone versus TID pirfenidone

    To compare the AUC of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered in a two-period crossover design.

    Time frame: 14 Days

  7. Part 2: Tmax of TID deupirfenidone versus TID pirfenidone

    To compare the Tmax of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered in a two-period crossover design.

    Time frame: 14 Days

  8. Part 3: AUC of TID deupirfenidone versus placebo

    To evaluate the AUC of two doses of deupirfenidone.

    Time frame: 6 Days

  9. Part 3: PK profile of TID deupirfenidone versus placebo

    To evaluate the Tmax of two doses of deupirfenidone.

    Time frame: 6 Days

Secondary outcomes

  1. Part 1: The effect of food on the Cmax of BID deupirfenidone versus TID pirfenidone

    To compare the Cmax of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.

    Time frame: 1 day

  2. Part 2: The effect of food on the Cmax of TID deupirfenidone versus TID pirfenidone

    To compare the Cmax of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.

    Time frame: 1 day

  3. Part 1: The effect of food on the AUC of BID deupirfenidone versus TID pirfenidone

    To compare the AUC of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.

    Time frame: 6 Days

  4. Part 1: The effect of food on the Tmax of BID deupirfenidone versus TID pirfenidone

    To compare the Tmax of 850 mg BID dosing of deupirfenidone to 801 mg TID dosing of pirfenidone at steady state, in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.

    Time frame: 1 Day

  5. Part 2: The effect of food on the AUC of TID deupirfenidone versus TID pirfenidone

    To compare the AUC of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.

    Time frame: 1 Day

  6. Part 2: The effect of food on the Tmax of TID deupirfenidone versus TID pirfenidone

    To compare the Tmax of 550 mg TID deupirfenidone to 801 mg TID pirfenidone at steady state in older healthy subjects, when administered with food on the last day of dosing prior to wash-out in a two-period crossover design.

    Time frame: 1 Day

07

Study locations

3 sites
  • Collaborative Neuroscience Network, LLC.
    Long Beach, California 90806, United States
  • Accel Research Sites
    Lake Mary, Florida 32746, United States
  • Hassman Research
    Berlin, New Jersey 08009, United States
08

References and documents

Individual participant data

Plan to share: No — This was a pharmacokinetic study with no health-based outcomes.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Jan 2022, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Mar 6, 2026
StartActual
Jul 12, 2021
Primary completionActual
Jan 1, 2022
CompletionActual
Jan 20, 2022
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07456800
Lead sponsor
PureTech
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Jul 12, 2021
Primary completion
Jan 1, 2022
Completion
Jan 20, 2022
Last update
Mar 6, 2026

Study contacts

Steven H Reynolds, DO
principal investigator · Collaborative Neuroscience Network, LLC.
Michael A Hassman, DO
principal investigator · Hassman Research
Bruce G Rankin, DO
principal investigator · Accel Research Sites

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion